X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (40) 40
oncology (40) 40
humans (31) 31
chemotherapy (28) 28
female (25) 25
male (24) 24
lung cancer (22) 22
middle aged (22) 22
aged (21) 21
cancer (21) 21
adult (18) 18
lung cancer, non-small cell (18) 18
care and treatment (17) 17
lung neoplasms - drug therapy (17) 17
lung neoplasms - genetics (17) 17
mutation (16) 16
lung neoplasms - pathology (15) 15
carcinoma, non-small-cell lung - drug therapy (14) 14
adenocarcinoma (13) 13
carcinoma, non-small-cell lung - genetics (13) 13
erlotinib (13) 13
open-label (12) 12
respiratory system (12) 12
aged, 80 and over (11) 11
analysis (11) 11
carcinoma, non-small-cell lung - pathology (11) 11
hematology, oncology and palliative medicine (11) 11
immunotherapy (11) 11
research (11) 11
gefitinib (10) 10
neoplasm staging (10) 10
prognosis (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
disease-free survival (9) 9
medical colleges (9) 9
multicenter (9) 9
patients (9) 9
receptor, epidermal growth factor - genetics (9) 9
survival (9) 9
abridged index medicus (8) 8
antimitotic agents (8) 8
antineoplastic agents (8) 8
apoptosis (8) 8
carboplatin (8) 8
lung neoplasms - mortality (8) 8
non-small cell lung cancer (8) 8
oncology, experimental (8) 8
tumors (8) 8
1st-line treatment (7) 7
cancer therapies (7) 7
genetic aspects (7) 7
metastasis (7) 7
adenocarcinoma - genetics (6) 6
antigens (6) 6
cell lung-cancer (6) 6
clinical trials (6) 6
egfr (6) 6
expression (6) 6
growth-factor receptor (6) 6
ligands (6) 6
lung neoplasms - metabolism (6) 6
protein kinase inhibitors - therapeutic use (6) 6
quinazolines - therapeutic use (6) 6
therapy (6) 6
treatment outcome (6) 6
biotechnology & applied microbiology (5) 5
crizotinib (5) 5
docetaxel (5) 5
double-blind method (5) 5
health aspects (5) 5
nsclc (5) 5
ovarian cancer (5) 5
paclitaxel (5) 5
respiratory tract diseases (5) 5
survival analysis (5) 5
tyrosine (5) 5
acquired-resistance (4) 4
antineoplastic agents - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
article (4) 4
carcinoma, non-small-cell lung - metabolism (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
cisplatin - administration & dosage (4) 4
deoxycytidine - administration & dosage (4) 4
deoxycytidine - analogs & derivatives (4) 4
drug administration schedule (4) 4
drug therapy (4) 4
epidermal growth factor (4) 4
gene mutations (4) 4
hematology (4) 4
immune checkpoint (4) 4
lung cancer, small cell (4) 4
lung-cancer (4) 4
lymphocytes (4) 4
non-small cell lung carcinoma (4) 4
product development (4) 4
quinazolines - administration & dosage (4) 4
receptor protein-tyrosine kinases - genetics (4) 4
retrospective studies (4) 4
studies (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 953 - 961
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 7, pp. 619 - 626
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 466 - 475
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 141 - 151
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 213 - 222
Summary Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free survival compared with pemetrexed and cisplatin for first-line... 
Hematology, Oncology and Palliative Medicine | GEFITINIB | MULTICENTER | SOLID TUMORS | ONCOLOGY | ADENOCARCINOMA | CLINICAL-TRIALS | INHIBITOR | ERBB FAMILY BLOCKER | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - ethnology | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Thailand - epidemiology | Asian Continental Ancestry Group - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Time Factors | Female | Odds Ratio | Republic of Korea - epidemiology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Carcinoma, Non-Small-Cell Lung - ethnology | Linear Models | Logistic Models | Treatment Outcome | China - epidemiology | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Intention to Treat Analysis | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Product development | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 528 - 538
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 830 - 838
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 8, pp. 735 - 742
Journal Article
Journal Article